Rofecoxib
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Rofecoxib
- Pharmacist Assessment Report
- Rofecoxib: From Rheumatoid Arthritis and Osteoarthritis to Heparin Cofactor 2 Deficiency
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Rofecoxib: From Rheumatoid Arthritis and Osteoarthritis to Heparin Cofactor 2 Deficiency
One-Sentence Summary
Rofecoxib is a selective COX-2 inhibitor (an NSAID) originally used for arthritic and inflammatory conditions such as rheumatoid arthritis, osteoarthritis and migraine. The TxGNN model predicts it may be effective for heparin cofactor 2 deficiency, but this is a model-only prediction with 0 clinical trials and 0 publications supporting it. The drug’s known prothrombotic safety signal also runs against this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, osteoarthritis, migraine, juvenile idiopathic arthritis, spondyloarthropathy (the product labels in India list no indication text) |
| Predicted New Indication | Heparin cofactor 2 deficiency |
| TxGNN Prediction Score | 0.9981 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general pharmacology, rofecoxib is a selective COX-2 inhibitor. Its efficacy in inflammatory joint disease and pain is well established.
Heparin cofactor 2 deficiency is an inherited thrombophilic disorder involving a serine protease inhibitor (SERPIND1). No credible mechanistic link exists between COX-2 inhibition and this condition. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Rofecoxib was withdrawn from many markets because of increased cardiovascular thrombotic risk. Using it in a prothrombotic condition would therefore raise a significant safety concern, so the prediction points in the wrong direction.
The other top-ranked predictions show the same pattern:
- Other thrombophilic disorders (factor 5 excess with spontaneous thrombosis, antithrombin deficiency type 2): no plausible mechanism, and the same safety concern applies.
- Congenital skeletal or developmental syndromes (for example brachydactyly-syndactyly syndrome, acromesomelic dysplasia Hunter-Thompson type, brachyolmia): an NSAID would not be expected to correct a genetic structural malformation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 92030 | Flexib 100mg Tablet | Strip of 15 tablets | Not specified |
| Registration No. 197698 | Rofejet Gel | Tube of 20 gm gel | Not specified |
| Registration No. 164793 | Oslol 20mg Tablet | Strip of 10 tablets | Not specified |
| Registration No. 171767 | Okabax 12.5mg Tablet | Strip of 10 tablets | Not specified |
| Registration No. 197904 | Roflam 50mg Tablet | Strip of 10 tablets | Not specified |
There are 20 valid single-ingredient registrations in total, including oral tablets and capsules and topical gels. The database lists the product as marketed, but rofecoxib has been withdrawn in most markets, so the actual market status should be verified.
Safety Considerations
- Drug Interactions: 246 interacting drugs were found. The 20 shown in the data compiled for this report are all Moderate level. They include:
- Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide
- Other anti-inflammatory drugs: acetylsalicylic acid, mesalazine, balsalazide
- Antidiabetic drugs: metformin, glimepiride, chlorpropamide, nateglinide
- Antibiotics: vancomycin, kanamycin, levofloxacin
- Bowel preparations: picosulfuric acid, polyethylene glycol with electrolytes, sodium sulfate
- Others: alosetron, naltrexone
- Class-level concern: Rofecoxib is associated with increased thrombotic cardiovascular events, which was the reason for its market withdrawal. This matters especially for any thrombophilic indication.
Package insert warnings and contraindications were not available, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a TxGNN model (deep learning) score, which may reflect similarities the model learned between related diseases, not biological evidence, with no clinical trials, no literature and no plausible mechanism. Rofecoxib’s prothrombotic signal makes it a safety concern, not a therapeutic opportunity, for thrombophilic conditions such as heparin cofactor 2 deficiency.
To proceed, the following is needed:
- Package insert warnings and contraindications from India’s regulatory sources (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence linking COX-2 inhibition to the predicted condition
- Verification of the current market and withdrawal status of rofecoxib in India
- Thrombotic and cardiovascular risk assessment before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.